Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Neukio Biotherapeutics

Main focus: Next-generation cell therapies for the treatment of cancer

Company stage: Pre-clinical

Diseases (gene editing): Haematological and solid cancers

Genome editing tool: Undisclosed

Funding stage: Private

Location: Shanghai, China


Gene-editing partnerships: EdiGene

Neukio Biotherapeutics is a Shanghai-based start-up company, which aims to develop next-generation natural killer (NK) cell-based therapies. The company's developmental programmes are currently undisclosed, but it has recently formed a collaboration with EdiGene to utilise its gene-editing capabilities.


HashtagNeukio Biotherapeutics

Company: Neukio Biotherapeutics
Search CRISPR Medicine